Pharma Stock Okays Double Treat For Shareholders With 1:5 Stock Split & 1:1 Bonus Issue; Shares Gain Over 5%

Anlon Healthcare Ltd, a small-cap company in the pharma sector, declared that a board meeting of the company was held on Friday, March 06, 2026 where the Board confirmed and approved a 1:5 stock split and 1:1 bonus shares. Anlon Healthcare Ltd (AHCL) is currently trading at Rs 122.80 on the NSE as of 9:44 AM IST on March 9, 2026, which is a strong gain of 5.28% from its previous closing price of Rs 116.64.

The stock has experienced considerable volatility, with an intraday high of Rs 124.00 and a low of Rs 113.40 during the early trade. It began the session at Rs 116.00. Currently, the company's market capitalization is around Rs 655.02 Cr. The stock is trading comfortably within its 52-week range, which comprises a high of Rs 172.75 and a low of Rs 90.78.

Anlon Healthcare Stock Split

The Board of Directors considered and approved "Sub-division of equity shares of the Company, such that 1 (One) equity share having face value of Rs.10/- (Rupees Ten Only) each, fully paid-up, be sub-divided into 5 (Five) equity shares having face value of Rs.02/- (Rupee Two Only) each fully paid up held by the shareholders of the Company as on the record date, to be determined later," Anlon Healthcare confirmed in a regulatory statement.

Prior to the subdivision, 5,50,00,000 equity shares with a face value of Rs 10 each made up the company's authorized share capital, totalling Rs 55,00,00,000. The face value of each equity share would be adjusted to Rs 2 following the proposed stock split, increasing the number of authorized shares to 27,50,00,000 equity shares while maintaining the same total authorized share capital of Rs 55,00,00,000.

Similarly, 5,31,51,500 equity shares with a face value of Rs 10 each make up the company's subscribed share capital, which is currently Rs 53,15,15,000. The total subscribed capital would stay at Rs 53,15,15,000 after the subdivision, but the number of subscribed shares will rise to 26,57,57,500 equity shares with a face value of Rs 2 each. The paid-up capital before the split was made up of 5,31,51,500 equity shares of Rs 10 apiece, totalling Rs 53,15,15,000. Following the subdivision, the total paid-up capital will stay at Rs 53,15,15,000, but the paid-up equity shares will rise to 26,57,57,500 shares of Rs 2 each.

Anlon Healthcare Bonus Issue

The Board of Directors also approved the "Issue of bonus equity shares in the ratio of 1:1 i.e., 1 (One) bonus equity shares of Rs. 02/- each for every 1 (one) equity share of Rs.02/- each fully paid-up held by the shareholders of the Company as on the record date, to be determined later," the pharma company has further informed to the stock exchanges.

The company proposes to issue 26,57,57,500 fully paid-up equity shares with a face value of Rs 2 apiece as part of the bonus issue corporate action. Before the bonus issue, the company's authorized share capital stood at 55,00,00,000 equity shares of Rs 2 each, amounting to Rs 110 crore, and this will remain unchanged even after the bonus issue.

Nonetheless, there will be a notable rise in the subscribed and paid-up share capital. The company held 26,57,57,500 equity shares prior to the bonus issue, which translated into a total equity share capital of Rs 53,15,15,000. The number of shares would double to 53,15,15,000 equity shares following the implementation of the 1:1 bonus issue, bringing the total equity share capital to Rs 1,06,30,30,000.

The corporation would use Rs 53.15 crore from its free reserves and/or share premium account to execute the bonus issue. The firm has free reserves and/or share premium available for capitalization of around Rs 147.08 crore as of December 31, 2025. Anlon Healthcare has further confirmed that bonus shares would be credited to the demat account of the eligible shareholders within 2 months from the date of approval of the Board, i.e., on or before May 6, 2026.

Anlon Healthcare Target Price

"Anlon Healthcare stock price is bullish on the Daily charts with strong support at 107.9. A daily close above resistance of 117 could lead to a target of 138 in the near term," recommended A R Ramachandran, part-time SEBI-registered Research Analyst, Tips2trades.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.